Treatment of Advanced or Metastatic Oesophageal Squamous-Cell Carcinoma with PD-L1 Negative/Low Expression

This protocol targets a specific sub-population: patients with advanced or metastatic oesophageal squamous-cell carcinoma (SCC) whose tumours show PD-L1 negative or low expression, defined by a Combined Positive Score (CPS) below 10 and a Tumour Proportion Score (TPS) below 1%.

Clinical scenario

Advanced or metastatic oesophageal SCC with PD-L1 CPS < 10 and TPS < 1%. The standard first-line approach for oesophageal SCC is a platinum–fluoropyrimidine doublet chemotherapy regimen. Post hoc evidence suggests no benefit in the PD-L1 CPS < 10 subgroup from certain combination strategies, making biomarker-stratified treatment selection relevant in this setting.

Treatment approach (partial)

The protocol specifies a monotherapy approach for eligible patients in this PD-L1 low/negative setting.

Full regimen details, eligibility criteria, and sequencing are available in the structured protocol →

Instant Access to Structured Evidence-Based Regimens

References

Standard first-line ChT for oesophageal SCC is a platinum–fluoropyrimidine doublet.
A post hoc analysis suggested no benefit in patients with a PD-L1 CPS <10.
Nivolumab is recommended for oesophageal SCC previously treated with platinum–fluoropyrimidine ChT [I, A; ESMO-MCBS v1.1 score: 3].

DOI: 10.1016/j.annonc.2022.07.003 View source ↗